Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
Ahmed Mohammed Elbarky1,2 1Vitreoretinal consultant, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 2Department of Ophthalmology, Benha Faculty of Medicine, Benha University, Benha, EgyptCorrespondence: Ahmed Mohammed Elbarky Email abarky@yahoo.comPurpose: The 0.19 mg fluocinolone ace...
Guardado en:
Autor principal: | Elbarky AM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2ece8fb91aa44df6876e3e866ee8e541 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho J, et al.
Publicado: (2019) -
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
por: Massin P, et al.
Publicado: (2016) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon H, et al.
Publicado: (2017) -
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
por: Adán A, et al.
Publicado: (2020) -
Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
por: Mushtaq B, et al.
Publicado: (2021)